Fineline Cube

Follow:
14486 Articles
Daiichi Sankyo’s Enhertu Wins CDE Acceptance for First‑Line HER2‑Positive Breast‑Cancer Indication in China
CompanyDrug

Daiichi Sankyo’s Enhertu Wins CDE Acceptance for First‑Line HER2‑Positive Breast‑Cancer Indication in China

Metsera Faces Escalating Bidding War as Novo Nordisk’s $10 B Offer Tops Pfizer’s Revised Proposal
CompanyDeals

Metsera Faces Escalating Bidding War as Novo Nordisk’s $10 B Offer Tops Pfizer’s Revised Proposal

Roche Announces a $55 M Partnership with Manifold Bio to Build BBB Shuttles
CompanyDeals

Roche Announces a $55 M Partnership with Manifold Bio to Build BBB Shuttles

Eli Lilly Announces Phase 3 ATTAIN‑PAD Trial for Oral GLP‑1 Agent orforglipron
CompanyDrug

Eli Lilly Announces Phase 3 ATTAIN‑PAD Trial for Oral GLP‑1 Agent orforglipron

Green Valley Faces Bribery Fine as Re‑registration Deadline Passes
Company

Green Valley Faces Bribery Fine as Re‑registration Deadline Passes

CARsgen Therapeutics Shares Promising Early Results for Allogeneic CAR‑T Products
CompanyDrug

CARsgen Therapeutics Shares Promising Early Results for Allogeneic CAR‑T Products

Guangzhou’s 12‑Step Plan to Accelerate Innovative Drug and Device Adoption
Policy / Regulatory

Guangzhou’s 12‑Step Plan to Accelerate Innovative Drug and Device Adoption

Hengrui Gets NMPA Green Light for Rezvilutamide‑HS‑20093 Combination Trial in Prostate Cancer
CompanyDrug

Hengrui Gets NMPA Green Light for Rezvilutamide‑HS‑20093 Combination Trial in Prostate Cancer

CStone Receives NMPA Approval for CS2009 Phase II Trial in Advanced Solid Tumors
CompanyDrug

CStone Receives NMPA Approval for CS2009 Phase II Trial in Advanced Solid Tumors

NHSA Re‑designs Drug‑Prescribing Surveillance, Targeting Illicit Use and Resale
Policy / Regulatory

NHSA Re‑designs Drug‑Prescribing Surveillance, Targeting Illicit Use and Resale

Amoy Diagnostics Announce NMPA Approval of China’s First KRAS G12C Companion Diagnostic
CompanyMedical Device

Amoy Diagnostics Announce NMPA Approval of China’s First KRAS G12C Companion Diagnostic

GenAns Biotechnology Receives FDA Fast‑Track Designation for GA001 Injection, a Promising Gene‑Therapy for Retinitis Pigmentosa
CompanyDrug

GenAns Biotechnology Receives FDA Fast‑Track Designation for GA001 Injection, a Promising Gene‑Therapy for Retinitis Pigmentosa